Exact Mass: 427.36613940000007

Exact Mass Matches: 427.36613940000007

Found 122 metabolites which its exact mass value is equals to given mass value 427.36613940000007, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

5-Methylheptadecanoylcarnitine

3-[(5-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


5-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-Methylheptadecanoylcarnitine

3-[(11-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


11-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

14-Methylheptadecanoylcarnitine

3-[(14-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


14-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 14-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 14-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 14-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Methylheptadecanoylcarnitine

3-[(9-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


9-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Methylheptadecanoylcarnitine

3-[(8-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


8-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

15-Methylheptadecanoylcarnitine

3-[(15-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


15-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 15-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 15-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 15-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Methylheptadecanoylcarnitine

3-[(10-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


10-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methylheptadecanoylcarnitine

3-[(7-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


7-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

13-Methylheptadecanoylcarnitine

3-[(13-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


13-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 13-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 13-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 13-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methylheptadecanoylcarnitine

3-[(3-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


3-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

16-Methylheptadecanoylcarnitine

3-[(16-Methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C25H49NO4 (427.36613940000007)


16-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 16-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 16-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 16-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methylheptadecanoylcarnitine

3-[(4-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


4-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 4-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Methylheptadecanoylcarnitine

3-[(6-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


6-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-Methylheptadecanoylcarnitine

3-[(12-methylheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


12-Methylheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-methylheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-Methylheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-Methylheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol

5-hydroxy-2,15-dimethyl-14-(6-methylhept-5-en-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-1(10)-ene-6-carboxylate

C28H43O3 (427.32120280000004)


4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as white lupine, chinese chives, radish, and pear, which makes 4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products.

   
   
   

O-stearoylcarnitine

O-stearoylcarnitine

C25H49NO4 (427.36613940000007)


An O-acylcarnitine having stearoyl (octadecanoyl) as the acyl substituent.

   

N-Methyl-solasodine

N-Methyl-solasodine

C28H45NO2 (427.345011)


   

(22R,25S)-N-methyl-22,26-epiminocholest-3,6-dione|puqietinedione

(22R,25S)-N-methyl-22,26-epiminocholest-3,6-dione|puqietinedione

C28H45NO2 (427.345011)


   

N-(1-hydroxy-3-methoxypropan-2-yl)-7-methoxyicos-4-enamide

N-(1-hydroxy-3-methoxypropan-2-yl)-7-methoxyicos-4-enamide

C25H49NO4 (427.36613940000007)


   
   

Geotrichum alkaloid A 25822D

Geotrichum alkaloid A 25822D

C28H45NO2 (427.345011)


   

Acylcarnitine C18:0

3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.36613940000007)


CONFIDENCE standard compound; INTERNAL_ID 256

   
   

Stearoyl-carnitine; AIF; CE0; CorrDec

Stearoyl-carnitine; AIF; CE0; CorrDec

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; AIF; CE10; CorrDec

Stearoyl-carnitine; AIF; CE10; CorrDec

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; AIF; CE30; CorrDec

Stearoyl-carnitine; AIF; CE30; CorrDec

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; AIF; CE0; MS2Dec

Stearoyl-carnitine; AIF; CE0; MS2Dec

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; AIF; CE10; MS2Dec

Stearoyl-carnitine; AIF; CE10; MS2Dec

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; AIF; CE30; MS2Dec

Stearoyl-carnitine; AIF; CE30; MS2Dec

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; LC-tDDA; CE10

Stearoyl-carnitine; LC-tDDA; CE10

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; LC-tDDA; CE20

Stearoyl-carnitine; LC-tDDA; CE20

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; LC-tDDA; CE30

Stearoyl-carnitine; LC-tDDA; CE30

C25H49NO4 (427.36613940000007)


   

Stearoyl-carnitine; LC-tDDA; CE40

Stearoyl-carnitine; LC-tDDA; CE40

C25H49NO4 (427.36613940000007)


   
   

(R)-Stearoylcarnitine

O-octadecanoyl-R-carnitine

C25H49NO4 (427.36613940000007)


   
   

CAR 18:0

3-stearoyloxy-4-(trimethylammonio)butyrate

C25H49NO4 (427.36613940000007)


   

Cer 26:0;O2

N-(tetradecanoyl)-tetradeca-sphinganine

C26H53NO3 (427.40252280000004)


   

N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]octanamide

N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]octanamide

C26H53NO3 (427.40252280000004)


   

4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol

5-hydroxy-2,15-dimethyl-14-(6-methylhept-5-en-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-1(10)-ene-6-carboxylate

C28H43O3 (427.32120280000004)


4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as white lupine, chinese chives, radish, and pear, which makes 4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products. 4α-carboxy-5α-cholesta-8,24-dien-3β-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4α-carboxy-5α-cholesta-8,24-dien-3β-ol can be found in a number of food items such as white lupine, chinese chives, radish, and pear, which makes 4α-carboxy-5α-cholesta-8,24-dien-3β-ol a potential biomarker for the consumption of these food products.

   

4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol

3-hydroxy-10,13-dimethyl-17-(6-methylhept-5-en-2-yl)-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-4-carboxylate

C28H43O3- (427.32120280000004)


4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as white lupine, chinese chives, radish, and pear, which makes 4alpha-carboxy-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products.

   
   

4alpha-carboxy-5alpha-cholesta-7,24-dien-3beta-ol

4alpha-carboxy-5alpha-cholesta-7,24-dien-3beta-ol

C28H43O3- (427.32120280000004)


   
   
   
   
   
   
   
   
   
   
   
   
   
   

4-[(2S)-2-[2-(4-ethoxyphenyl)ethylamino]-3-[[(2S)-1-(methylamino)hexan-2-yl]amino]propyl]phenol

4-[(2S)-2-[2-(4-ethoxyphenyl)ethylamino]-3-[[(2S)-1-(methylamino)hexan-2-yl]amino]propyl]phenol

C26H41N3O2 (427.3198606)


   

4-Carboxyzymosterol(1-)

4-Carboxyzymosterol(1-)

C28H43O3- (427.32120280000004)


A steroid acid anion that is the conjugate base of 4-carboxyzymosterol, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   
   

N-(1,3-dihydroxynonan-2-yl)heptadecanamide

N-(1,3-dihydroxynonan-2-yl)heptadecanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxytetracosan-2-yl)acetamide

N-(1,3-dihydroxytetracosan-2-yl)acetamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxyhenicosan-2-yl)pentanamide

N-(1,3-dihydroxyhenicosan-2-yl)pentanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxytricosan-2-yl)propanamide

N-(1,3-dihydroxytricosan-2-yl)propanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxyicosan-2-yl)hexanamide

N-(1,3-dihydroxyicosan-2-yl)hexanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxydocosan-2-yl)butanamide

N-(1,3-dihydroxydocosan-2-yl)butanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxyheptadecan-2-yl)nonanamide

N-(1,3-dihydroxyheptadecan-2-yl)nonanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxyoctan-2-yl)octadecanamide

N-(1,3-dihydroxyoctan-2-yl)octadecanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxynonadecan-2-yl)heptanamide

N-(1,3-dihydroxynonadecan-2-yl)heptanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxyhexadecan-2-yl)decanamide

N-(1,3-dihydroxyhexadecan-2-yl)decanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxytridecan-2-yl)tridecanamide

N-(1,3-dihydroxytridecan-2-yl)tridecanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxydodecan-2-yl)tetradecanamide

N-(1,3-dihydroxydodecan-2-yl)tetradecanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxyundecan-2-yl)pentadecanamide

N-(1,3-dihydroxyundecan-2-yl)pentadecanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxydecan-2-yl)hexadecanamide

N-(1,3-dihydroxydecan-2-yl)hexadecanamide

C26H53NO3 (427.40252280000004)


   

N-(1,3-dihydroxypentadecan-2-yl)undecanamide

N-(1,3-dihydroxypentadecan-2-yl)undecanamide

C26H53NO3 (427.40252280000004)


   
   
   
   

(8Z,11Z,14Z,17Z,20Z,23Z)-N-(2-hydroxyethyl)hexacosa-8,11,14,17,20,23-hexaenamide

(8Z,11Z,14Z,17Z,20Z,23Z)-N-(2-hydroxyethyl)hexacosa-8,11,14,17,20,23-hexaenamide

C28H45NO2 (427.345011)


   
   

N-(dodecanoyl)-tetradecasphinganine

N-(dodecanoyl)-tetradecasphinganine

C26H53NO3 (427.40252280000004)


   

N-octanoyldihydrosphingosine

N-octanoyldihydrosphingosine

C26H53NO3 (427.40252280000004)


A dihydroceramide in which the N-acyl group is specified as octanoyl.

   

O-octadecanoyl-L-carnitine

O-octadecanoyl-L-carnitine

C25H49NO4 (427.36613940000007)


An O-acyl-L-carnitine in which the acyl group is specified as stearoyl (octadecanoyl).

   

CarE(18:0)

CarE(18:0)

C25H49NO4 (427.36613940000007)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

O-stearoyl-L-carnitine

(3R)-3-(octadecanoyloxy)-4-(trimethylazaniumyl)butanoate

C25H49NO4 (427.3661394)


-

   

(3s,4as,6ar,6bs,9s,10ar,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

(3s,4as,6ar,6bs,9s,10ar,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

C28H45NO2 (427.345011)


   

(7s,8as)-5-{[(4s,6r,8s,9as)-8-methyl-6-[(2s)-piperidin-2-ylmethyl]-octahydro-1h-quinolizin-4-yl]methyl}-1,7-dimethyl-3,4,6,7,8,8a-hexahydro-2h-quinoline

(7s,8as)-5-{[(4s,6r,8s,9as)-8-methyl-6-[(2s)-piperidin-2-ylmethyl]-octahydro-1h-quinolizin-4-yl]methyl}-1,7-dimethyl-3,4,6,7,8,8a-hexahydro-2h-quinoline

C28H49N3 (427.39262740000004)


   

(3s,4as,6ar,6bs,9s,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,7h,8h,9h,11h,11ah-cyclohexa[a]fluoren-5-one

(3s,4as,6ar,6bs,9s,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,7h,8h,9h,11h,11ah-cyclohexa[a]fluoren-5-one

C28H45NO2 (427.345011)


   

(3s,4as,6as,6br,9s,10ar,11ar,11br)-9-[(1s)-1-[(2s,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

(3s,4as,6as,6br,9s,10ar,11ar,11br)-9-[(1s)-1-[(2s,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

C28H45NO2 (427.345011)


   

9-[1-(1,5-dimethylpiperidin-2-yl)ethyl]-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,7h,8h,9h,11h,11ah-cyclohexa[a]fluoren-5-one

9-[1-(1,5-dimethylpiperidin-2-yl)ethyl]-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,7h,8h,9h,11h,11ah-cyclohexa[a]fluoren-5-one

C28H45NO2 (427.345011)


   

(2r,3r)-2-[(2-methoxy-2-oxoethyl)amino]tetradecan-3-yl octanoate

(2r,3r)-2-[(2-methoxy-2-oxoethyl)amino]tetradecan-3-yl octanoate

C25H49NO4 (427.36613940000007)


   

9-[1-(1,5-dimethylpiperidin-2-yl)ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

9-[1-(1,5-dimethylpiperidin-2-yl)ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

C28H45NO2 (427.345011)


   

1,7-dimethyl-5-{[8-methyl-6-(piperidin-2-ylmethyl)-octahydro-1h-quinolizin-4-yl]methyl}-3,4,6,7,8,8a-hexahydro-2h-quinoline

1,7-dimethyl-5-{[8-methyl-6-(piperidin-2-ylmethyl)-octahydro-1h-quinolizin-4-yl]methyl}-3,4,6,7,8,8a-hexahydro-2h-quinoline

C28H49N3 (427.39262740000004)


   

(3s,4as,6ar,6bs,9s,11as,11br)-9-[(1r)-1-[(2s,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,7h,8h,9h,11h,11ah-cyclohexa[a]fluoren-5-one

(3s,4as,6ar,6bs,9s,11as,11br)-9-[(1r)-1-[(2s,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,7h,8h,9h,11h,11ah-cyclohexa[a]fluoren-5-one

C28H45NO2 (427.345011)


   

(3s,4as,6ar,6br,9s,10ar,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

(3s,4as,6ar,6br,9s,10ar,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

C28H45NO2 (427.345011)


   

(3s,4as,6ar,6bs,9s,10ar,11as,11br)-9-[(1s)-1-(1,5-dimethylpiperidin-2-yl)ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

(3s,4as,6ar,6bs,9s,10ar,11as,11br)-9-[(1s)-1-(1,5-dimethylpiperidin-2-yl)ethyl]-3-hydroxy-10a,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluoren-5-one

C28H45NO2 (427.345011)